



**3<sup>rd</sup> WHO Meeting on evaluation of pandemic influenza vaccines in clinical trials  
WHO/HQ, Geneva, Salle A, Main Building**

**15 & 16 FEBRUARY 2007**

**PARTICIPANTS**

**Dr Angelika BANZHOFF**, Head of Development Pandemic Influenza Vaccines, Novartis Vaccines, PO Box 1630, 35006 Marburg, Germany

**Dr Ian BARR**, Deputy Director, WHO Influenza Centre, 45 Poplar Road, Parkville, Melbourne, Australia

**Dr Noel BARRETT**, Vice President R&D, Baxter Vaccines, Biomedical Research Center, Uferstrasse 15, Orth /Donau A 2304, Austria,

**Dr Tagir A. BEKTIMIROV**, Deputy Director, L.A. Tarassevich State Research Institute for Standardization and Control of Medical Biological Preparations, 41 Sivtsev Vrazhek, 119002 Moscow, Russian Federation

**Dr David BERNSTIEN**, Children's Hospital Medical Center, Director, Division of Infectious Diseases, 3333 Burnet Avenue, ML 6014, Cincinnati, OH 45229 3039

**Dr John BOSLEGO**, Director, Vaccine Development Strategic Program, Program for Appropriate Technology in Health, PATH, 1800 K Street NW, Suite 800, Washington DC 20006, USA

**Dr Tim BROOKS**, Head, Novel and Dangerous Pathogens, Centre for Emergency Preparedness and Response Health Protection Agency, Porton Down Salisbury Wiltshire, SP4 0JG, United Kingdom

**Dr Iris A. de BRUIJN**, Global Clinical Director, Influenza Vaccines, Solvay Pharmaceuticals, B.V. Clinical Development, PO Box 900, 1380 DA Weesp, Netherlands

**Dr Piet L.B. BRUIJNZEEL**, Director, Clinical Research Immunology Department Translational Medicine, Nobilon/Organon, N.V. Organon, Molenstraat 110, 5340 BH Oss, Netherlands

**Dr Kim BUSH**, President Vaccines SBU, Baxter Healthcare Corporation, 12140 Indian Creek Court, Beltsville, MD 20705, USA

**Dr James CAMPBELL**, Assistant Professor of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, University of Maryland, Center for Vaccine Development, Health Sciences Facility Room 480, 685 West Baltimore Street, Baltimore, Maryland 21201-1509 USA

**Dr Tony COLEGATE**, Influenza Technical Affairs Manager, Chiron Vaccines Gaskill Road, Speke, Liverpool. L24 9GR, United Kingdom

**Dr Manon COX**, Chief Operating Officer, Protein Sciences Corporation, 1000 Research Parkway, Meriden CT 06450, USA

**Dr Nancy J. COX**, Director, Influenza Division, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, 1600 Clifton Rd. NE, Atlanta, GA 30333, USA

**Dr Cecil CZERKINSKY**, Deputy Director General, International Vaccine Institute Laboratory Sciences Division, SNU Research Park, San 4-8 Bongcheon-7 dong Kwanak-gu, Seoul 151-818, Republic of Korea

**Dr Gabriella DÉTARI**, Head of Inspectorate Department, National Institute of Pharmacy Zrinyi utca 3, Budapest, H - 1051, Hungary

**Dr Othmar ENGELHARDT**, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK

**Dr David. S FEDSON**, 57 chemin du Lavoir, 01630 Sergy-Haut, France

**Dr Neil FORMICA**, Medical Associate, Influenza Vaccine Program, Research and Development, CSL Limited, 45 Poplar Road, Parkville, Victoria 3052, Australia

**Dr Bruce GELLIN**, Director, Vanderbilt University Medical School, Hubert H. Humphrey Building, 200 Independence Ave, SW - Room 736E, Washington DC 20201-0004, USA

**Dr Catherine Gerdil-Lacroix**, Sanofi Pasteur, Campus Mérieux, 1541, avenue Marcel Mérieux, F-69280 Marcy l'Etoile, France

**Dr Giuseppe DEL GIUDICE**, Head, Translational Medicine, Novartis Vaccines Research Center, Via Fiorentina 1, 53100 Siena, Italy

**Dr Jesse GOODMAN**, Director, Center for Biologics Evaluation and Research Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852 USA

**Dr Toru GOTANDA**, Deputy Director, Research Center for Biologicals, The Kitasato Institute Research for Biologicals, 6-111, Arai, Kitamoto-Shi, Saitama 364-0026, Japan

**Dr Gary GROHMANN**, Therapeutic Goods Administration, P.O. Box 100, Woden ACT 2606 Australia

**Dr Ian GUST**, Department of Microbiology and Immunology, Room 115, The University of Melbourne, Victoria 3010, Australia

**Dr Alan HAMPSON**, Interflu Pty Ltd, 6 Monica Street, East Doncaster, Victoria 3109, Australia,

**Dr Bjorn HANEBERG**, Division for Infectious Disease Control, Norwegian Institute of Public Health, P.O.Box 4404-Nydalen, NO-0403 Oslo, Norway

**Dr Norbert HEHME**, Vice President, Flu Manufacturing Strategy, GSK Biologicals, Zirkusstrasse 40 GE - 01069 Dresden, Germany

**Dr Luc HESSEL**, Executive Director, Medical and Public Affairs, Europe, Sanofi Pasteur MSD, 8 rue Jonas Salk, F-69367 Lyon Cedex 07, France. Chairman of the Influenza Vaccine Supply International Task Force, IFPMA, Geneva

**Dr Alan HAY**, Director, WHO CC for Reference and Research on Influenza, National Institute for Medical Research, National Institute for Medical Research, The Ridgeway, Mill Hill, London, NW7 1AA, United Kingdom

**Dr Agnès HOFFENBACH**, Sanofi Pasteur, 1541 avenue Marcel Merieux, 69280 Marcy l'Etoile, France

**Mr Kazuo HOSOI**, General Manager, Denka-Seiken Co. Ltd, 1-2-2, Minami Honcho, Goshen-Shi, Nigata 959-1695 Japan

**Dr Ruth KARRON**, Johns Hopkins Bloomberg School of Public Health, Center for Immunization Research, Hampton House, Room 217, International Health, 624 N. Broadway Baltimore, Maryland 21205, USA

**Dr Wendy A. KEITEL**, Associate Professor of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, One Baylor Plaza, Room 221D (MS BCM 280) Houston, TX 77030, USA

**Dr Anne KELSO**, Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, 300 Herston Road, Herston, Queensland 4029, Australia

**Dr Terhi KILPI**, Senior Researcher, Department of Vaccines, National Public Health Institute Mannerheimintie 166, Fin 00300 Helsinki, 00171 Helsinki, Finland

**Dr Otfried KISTNER**, Senior Director Virology/Viral Vaccines, Baxter BioScience, Baxter AG, Biomedical Research Center, Uferstrasse 15, Orth /Donau A 2304, Austria,

**Dr Alexander KLIMOV**, Chief, Strain Surveillance Section, Influenza Branch, G-16, DVRD, NCID, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA 30333

**Dr Sergey KOROVKIN**, Head of Control & Registration Department, Microgen State Company, Zubovskiy blvd, 4 119021 Moscow, Russia

**Dr Igor KRASILNIKOV**, 1-ja Dubrovskaja st. 15, 115088 Moscow, Russia

**Dr Ryoko KRAUSE**, Director, Biologicals and Vaccines, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Ch. Louis-Dunant 15, P.O. Box 195, CH 1211 Geneva 20, Switzerland

**Dr Jacques LAPIERRE**, Production Director, GSK Biologicals North America, 2323 Du Parc, Technologique Blvd, Ste-Foy, Québec, Canada G1P 4R8

**Dr Roland LEVANDOWSKI**, Chief, Influenza, SARS, and Other Viral Respiratory Diseases Section, Division of Microbiology and Infectious Diseases, NIAID/NIH/DHHS, Room 5051 6610 Rockledge Drive, Bethesda, MD 20817, USA

**Dr James T. MATTHEWS**, Director, External Research & Development, Sanofi Pasteur Inc., Discovery Drive, Building 45, Room 219, P.O. Box 187, Swiftwater, Pennsylvania 18370-0187, USA

**Dr Arnold MONTO**, Chairman, The University of Michigan, UM School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109-2029, USA

**Dr Terry NOLAN**, Head, School of Population Health, University of Melbourne, Level 2, 207 Bouverie Street, Carlton, VIC 3010, Australia,

**Dr Albert OSTERHAUS**, Head of the Department of Virology, Erasmus University, Dr Molewaterplein 50, P.O. Box 1738, Rotterdam, 3015 GE, The Netherlands

**Ms Cathy PATTERSON**, Minister-Counsellor (Health) Australian Permanent Mission to the United Nations, Geneva, Switzerland

**Dr Eric PELFRENE**, Safety and Efficacy of Medicines Sector, Pre-Authorization Human Unit, EMEA, 7 Westferry Circus, Canary Wharf, London, E14 7HB, United Kingdom

**Dr Yuri PERVIKOV**, 23 bis, rue Pestalozzi, 10202, Geneva, Switzerland

**Dr Isaias RAW**, Director, Instituto Butantan, Av. Vital Brazil 1500, São Paulo 05503-900, Brazil

**Dr Steven G. REED**, Executive Vice-President and Dir. of Antigen Discovery Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle WA 98104, USA

**Dr Robin ROBINSON**, Acting Associate Director, Pandemic Influenza, Office of Public Health Emergency Medical Countermeasures, Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, 300 Independence Avenue, SW Room 640G, Washington DC, 20201 USA

**Dr Larisa Georgievna RUDENKO**, Head, Department of Virology, Russian Academy of Medical Science, Institute for Experimental Medicine, Academy Pavlov Str.12  
197376 St Petersburg, Russia

**Dr David RYAN**, CSL Limited, R&D, Director Product Development, 45 Poplar Road, Parkville, Victoria 3052, Australia

**Dr David SALISBURY**, Director of Immunisation, Department of Health, 510, Wellington House, 133-155, Waterloo Road, London SE1 8UG

**Dr Pathom SAWANPANYALERT**, Director, National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Tiwanon Road, Muang Nonthaburi 11000, Thailand

**Dr Corina SCHMIDT**, Technical Regulatory Strategy Unit Influenza, GSK Biologicals, Rue de l'Institut 89, B-1300 Rixensart, Belgium

**Dr Ulf SCHRÖDER**, Associate Prof., CSO & Founder, Eurocine Vaccines AB, Karolinska Science Park, 171 77 Stockholm, Sweden

**Dr James SIMON**, ViroClinics BV, Dr. Molewaterplein 50, Room Ee1985, 3015 GE Rotterdam, Netherlands

**Dr Iain STEPHENSON**, Infectious Disease Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom

**Mr Lin SU**, Manager Assistant, Sinovac Biotech Limited, No. 39 Shangdi Xi Road, Haidian District Beijing 100085, People's Republic of China

**Dr Kanta SUBBARAO**, Senior Investigator, Laboratory of Infectious Diseases, NIAID, NIH, Bldg. 50, Room 6132, 50 South Drive, MSC 8007, Bethesda, MD 20892

**Mr Yoshikayu TADA**, Manager, Research & Production, Technology Division Biken, Kanonji Institute, 2-9-41, Yahata-cho, Kanonji, Kagawa 768-0061, Japan

**Dr Theresa TAM**, Director, Immunization and Respiratory Infections Division, Public Health Agency of Canada, 100 Eglantine Driveway, Ottawa, Ontario, K1A 0K9, Canada

**Dr Yoshitake TANAKA**, Manager, Licensing and Planning Division, Research Center for Biologicals, Kitasato Institute, Saitama, Japan

**Dr Masato TASHIRO**, Director, Department of Viral Diseases and Vaccine Control

منظمة الصحة العالمية • 世界卫生组织

Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud

National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashi-Murayama,  
Tokyo 208-0011, Japan

**Dr Haruka TOYODA**, Senior Reviewer, Pharmaceuticals and Medical Devices Agency  
Office of Biologics Review, Tokyo, Japan

**Dr John TREANOR**, Professor of Medicine, University of Rochester Medical Centre  
601 Elmwood Avenue, Room 3-6309, Rochester, NY 14642, USA

**Dr Fons UYTDEHAAG**, Director Scientific Affairs, Crucell/Berna Biotech, Archimedesweg 4, PO Box  
2048 2301 CA, Leiden, The Netherlands

**Dr Friso VANVOORTHUIZEN**, Global Director Pandemic Preparedness & Manufacturing Liaison,  
Solvay Pharmaceuticals BV, C.J. van Houtenlaan 36, Weesp 1381 CP, The Netherlands

**Professor Robert WEBSTER**, St Jude's Children's Research Hospital, 332 North Lauderdale, Memphis,  
Tennessee 38105 27 94, USA

**Dr John WOOD**, Division of Virology, National Institute for Biological Standards &  
Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, United Kingdom

**Dr Joanne Xiaojuan XIONG**, Clinical Evaluation Division, Centre for Biologics Evaluation, Biologics  
and Genetic Therapies Directorate, Health Canada, 100 Eglantine Driveway, A/L 0603B2, Tunney's  
Pasture Ottawa, Canada K1A 0K9

**Dr Zhipping YE**, Laboratory of Respiratory Viruses, Food and Drug Administration, Bldg 29A, Room  
2817, 880 Rockville, Bethesda, MD 20892, USA

**Dr Shu YEULONG**, Director, National Influenza Center, 100 Yingxin Street, Xuanwu District, Beijing,  
China

**Dr Maria ZAMBON**, Respiratory Virus Unit, HPA, 61 Colindale Avenue, Colindale, London, NW9  
5HT, United Kingdom

**Dr Vitaly Vasilievich ZVEREV**, Director, Mechnikov Research Institute of Vaccines and Sera, Kezenny  
Pereulok, 5a Moscow, Russia

### **REGIONAL OFFICE STAFF**

**Dr Caroline BROWN**, EURO, World Health Organization, Regional Office for Europe, 8  
Scherfigsvej, DK-2100 Copenhagen, Denmark

**Dr Maria de los Angeles CORTES**, AMRO, World Health Organization, Regional Office for  
the Americas, Pan American Sanitary Bureau 525, 23rd Street, Washington

**Dr Yoshikuni SATO**, WPRO, World Health Organization, United Nations Avenue, P.O.Box 2932, 1000  
Manila, Philippines

**Dr Weigong Zhou**, WPRO, World Health Organization, United Nations Avenue, P.O.Box 2932, 1000  
Manila, Philippines

**SECRETARIAT**

**Mr Alejandro Javier COSTA**, WHO Global Influenza Programme, Department for Communicable Disease Surveillance and Response, CDS/EPR/GPI, World Health Organization, Avenue Appia 20, CH 1211 Geneva 27, Switzerland, Tel:+ 41 22 791 4965, Fax:+ 41 22 791 4878, E-Mail: costaa@who.int

**Dr Martin FRIEDE**, Product Research and Development (RPD), Initiative for Vaccine Research (IVR), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland  
Tel: +41 22 791 4398, Fax: +41 22 791 41 93, E-Mail: friedem@who.int

**Dr Keiji FUKUDA**, Global Influenza Programme (GIP), World Health Organization, 20 Ave Appia, 1211 Geneva 27, Switzerland, Tel: +41 22 791 3871, Fax: +41 22 791 4878, E-Mail: fukudak@who.int

**Dr David HEYMANN**, Polio Eradication Initiative (POL), World Health Organization, 20 Ave Appia, 1211 Geneva 27, Switzerland, Tel: +41 22 791 2212, Fax: +41 22 791 41 93, E-Mail: heymannd@who.int

**Dr Joachim HOMBACH**, Acting Coordinator, Implementation Research (IMR), Initiative for Vaccine Research (IVR), World Health Organization, 20 Avenue Appia, 1211 Genève 27, Switzerland  
Tel:+ 41 22 791 4531, Fax:+41 22 791 4860, E-Mail: hombachj@who.int

**Dr Marie-Paule KIENY**, Director, Initiative for Vaccine Research (IVR), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, Tel: +41 22 791 3591, Fax: +41 22 791 41 93  
E-Mail kienym@who.int

**Dr Daniel LAVANCHY**, Emerging and Dangerous Pathogens (EDP), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, Tel: +41 22 791 2656, Fax: +41 22 791,  
E-Mail: lavanchyd@who.int

**Dr Jean-Marie OKWO-BELE**, Director, Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland, Tel: + 41 22 791 27 79, Fax: + 41 22 791 42 27, E-Mail: okwobelej@who.int

**Dr Laszlo PALKONYAY**, Product Research and Development (RPD), Initiative for Vaccine Research (IVR), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland  
Tel: +41 22 791 3488, Fax: +41 22 791 4860, E-Mail: palkonyayl@who.int

**Dr David WOOD**, Acting Coordinator, Quality Assurance & Standards (QSS), Immunization, Vaccines and Biologicals, World Health Organization, 20 Ave Appia, 1211 Geneva 27, Switzerland  
Tel: +41 22 791 4050, Fax: +41 22 791 4971, E-Mail: woodd@who.int

**Dr Wenqing ZHANG**, Global Influenza Programme (GIP), World Health Organization, 20 Ave Appia, 1211 Geneva 27, Switzerland, Tel: +41 22 791 4282, E-Mail: zhangw@who.int